Last reviewed · How we verify
NCT05033925
Ficus Septica Leaves Fraction as a Complementary Therapy for Stadium IV Breast Cancer Patients
Phase 1, PHASE2 trial testing FADA (active fraction of Ficus septica leaf) 800 mg/day in Breast Cancer Stage IV in 324 participants. Status unknown.
30 December 2024
Quick facts
| Lead sponsor | Gadjah Mada University |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | supportive care |
| Enrollment | 324 |
| Start date | 25 October 2021 |
| Primary completion | 30 December 2024 |
| Estimated completion | 30 December 2025 |
| Sites | 1 location across Indonesia |
Drugs / interventions tested
- FADA (active fraction of Ficus septica leaf) 800 mg/day
- FADA (active fraction of Ficus septica leaf) 2000 mg/day
- Placebo capsule
Conditions studied
- Breast Cancer Stage IV — all drugs for Breast Cancer Stage IV →
Sponsor
Gadjah Mada University
Who can join
18 and older, female only, with Breast Cancer Stage IV. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this research is to assess the safety profile and clinical benefit of Awar-Awar leaf active fraction as a complementary therapy in chemotherapy of stage IV breast cancer
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05033925
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer Stage IV
Currently open trials in the same condition.
- NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
- NCT07371585 — Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management · Phase 2 · recruiting
- NCT06830382 — HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC · recruiting
- NCT06889688 — Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast · Phase 3 · active not recruiting
- NCT06678269 — A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer · Phase 1 · recruiting
Other Gadjah Mada University trials
Trials by the same sponsor.
- NCT07476573 — Clinical Trial of Lactiplantibacillus Plantarum Dad-13 on Gut Microbiota Profile and Performance in Adolescent Athletes · NA · not yet recruiting
- NCT07198828 — Mobile Health (mHealth) Application for Smoking Cessation Among Adolescents in Indonesia · NA · not yet recruiting
- NCT07373080 — Brief Culturally Adapted Behavioral Activation Therapy for Adults With Depression in Rural Indonesian Primary Care: A Ty · NA · not yet recruiting
- NCT07349082 — Sensory Block Onset: Epidural vs Dural Puncture Epidural in Cesarean Section · NA · not yet recruiting
- NCT07320534 — Levofloxacin Prophylaxis to Prevent First Febrile Neutropenia in Pediatric ALL During Induction Phase · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05033925 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gadjah Mada University
- Last refreshed: 28 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05033925.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing